Qiagen (QGEN) Expected to Announce Earnings on Wednesday

Qiagen (NYSE:QGEN) is expected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.60 per share and revenue of $527.6460 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting analysts’ consensus estimates of $0.54. The business had revenue of $492.32 million for the quarter, compared to analysts’ expectations of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same period last year, the business earned $0.56 earnings per share. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Qiagen Trading Up 2.6%

QGEN stock opened at $42.16 on Wednesday. The company has a market capitalization of $8.69 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 4.10 and a beta of 0.64. Qiagen has a one year low of $32.53 and a one year high of $57.81. The company’s 50 day moving average price is $38.43 and its two-hundred day moving average price is $41.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21.

Qiagen Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were paid a $0.35 dividend. This is a positive change from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a dividend yield of 90.0%. Qiagen’s dividend payout ratio is currently 18.32%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on QGEN. Morgan Stanley raised shares of Qiagen from an “overweight” rating to an “overweight” rating and increased their target price for the company from $40.00 to $42.00 in a report on Tuesday, June 23rd. Stifel Nicolaus set a $36.00 price target on shares of Qiagen and gave the stock a “hold” rating in a research note on Monday, May 18th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. Finally, Berenberg Bank set a $45.50 price objective on Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Qiagen has a consensus rating of “Hold” and an average price target of $43.34.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QGEN. Commerce Bank grew its holdings in shares of Qiagen by 4.9% in the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after purchasing an additional 314 shares during the last quarter. Private Advisor Group LLC raised its holdings in Qiagen by 7.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock valued at $256,000 after buying an additional 378 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in Qiagen by 0.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 218,591 shares of the company’s stock valued at $9,737,000 after buying an additional 594 shares during the period. Zacks Investment Management boosted its position in Qiagen by 0.6% during the 3rd quarter. Zacks Investment Management now owns 135,207 shares of the company’s stock valued at $5,996,000 after buying an additional 742 shares during the period. Finally, Janney Montgomery Scott LLC boosted its position in Qiagen by 16.5% during the 4th quarter. Janney Montgomery Scott LLC now owns 5,481 shares of the company’s stock valued at $247,000 after buying an additional 778 shares during the period. Institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.